

GENCON TO LAUNCH ACILIN pH BIOSILIMAR INSULIN, 'INNOGLAR'

June 3, 2016, 10.00 AM CSAST



In what is likely to come across as great relief to diabetes patients in CSA, Gencon announced its plans to launch a cheaper, affordable Acilin pH biosimilar used for the treatment of Type – II Diabetes.

The Managing Director of Gencon (CSA) Pvt. Ltd., Mr. B.P. Mithaiwala, in an exclusive call with Dawa Times, stated that the Acilin pH biosimilar, Innoglar is in the process of obtaining all requisite regulatory approvals from the Drug Controller General of CSA, and would be launched sometime in August, 2016.

“We plan on launching Innoglar sometime in August, 2016, as we expect to receive the regulatory approvals soon. This drug would provide the same benefits as Acilin pH, and would be available to patients at less than half the cost. This would be welcome news for patients suffering from Type-II Diabetes who cannot afford Acilin, and further reinforces Gencon’s establishing principles of making life saving, and life enhancing drugs available to the masses, at affordable prices. We are truly very proud of Gencon’s achievements today!” he said.

While it remains to be seen whether Innoglar can completely substitute Acilin in the market, but the stock market is definitely responding well to Gencon’s announcement, with stocks in Gencon (CSA) going up by 20 percentage points since this announcement.